SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNAPRNewsWire • 08/01/24
S&P 500 Gains and Losses Today: Moderna Drops as Soft Vaccine Demand Prompts Guidance CutInvestopedia • 08/01/24
Stock Of The Day: Moderna Stock Plunges, Breaking Key Support Levels Following Earnings ReportBenzinga • 08/01/24
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly BeatInvestors Business Daily • 08/01/24
Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine marketCNBC • 08/01/24
Moderna Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAccesswire • 08/01/24
Leveragen Announces Collaboration Agreement with Moderna Using Proprietary Fully Human Single Domain Antibody Technology to Advance TherapeuticsBusiness Wire • 07/30/24
Exploring Analyst Estimates for Moderna (MRNA) Q2 Earnings, Beyond Revenue and EPSZacks Investment Research • 07/29/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNAGlobeNewsWire • 07/26/24